Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Pyaterochka launches new franchise format

6/27/24 X5

VseInstrumenty.ru began accepting applications for participation in the IPO

6/27/24 VSEH

Bank Saint-Petersburg established a leasing company

6/26/24 BSPB

Medsi will develop the resort area

6/26/24 AFKS

Nizhny Novgorod Refinery launches AVT-6 unit

6/26/24 LKOH

VK launched a unified authorization service for businesses and developers

6/26/24 VKCO

Softline will create a platform for automation of business processes in the retail industry

6/26/24 SOFL

Rostelecom plans to buy a data center for 4,000 racks

6/26/24 RTKM

Shareholders of Sovcombank approved dividends for 2023

6/26/24 SVCB

Shareholders of Stavropolenergosbyt approved dividends for 2023

6/25/24 STSB